Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma

The fibroblast growth factor receptor (FGFR) signaling pathway is aberrantly activated in approximately 15–20% of intrahepatic cholangiocarcinoma patients. Currently, several FGFR kinase inhibitors are being assessed in clinical trials for patients with FGFR-altered cholangiocarcinoma. Despite evide...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Cancer Ther
Prif Awduron: Krook, Melanie A., Lenyo, Alexandria, Wilberding, Max, Barker, Hannah, Dantuono, Mikayla, Bailey, Kelly M., Chen, Hui-Zi, Reeser, Julie W., Wing, Michele R., Miya, Jharna, Samorodnitsky, Eric, Smith, Amy M., Dao, Thuy, Martin, Dorrelyn M., Ciombor, Kristen K., Hays, John, Freud, Aharon G., Roychowdhury, Sameek
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7359896/
https://ncbi.nlm.nih.gov/pubmed/31911531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0631
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg